Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment

Nasal Administration of Dexamethasone for MS Treatment

Status

Withdrawn

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00674141

Enrollment

Registered

2008-05-07

Start date

2008-07-31

Completion date

2009-01-31

Last updated

2010-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MS Patient With Relpasing Remitting Attacks

Keywords

Multiple Sclerosis, relapsing remitting, Dexamethasone

Brief summary

The study aims to assess the safety and efficacy of nasale administration of Dexamethasone in relapsing MS patients

Interventions

DRUGDexamethasone soduim phosphate

nasale administation of Dexamethasone in 20mg dose/day (in two divided doses) fpr sevem days of treatment

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* MS patients with esatblished relapsing remitting attacks * increase in EDSS of at least 1 point for a least one day

Exclusion criteria

* children under 18 * pregnant patients * patients with diabetes * known allergy to steroids * patients who received steroids within 3 months prior to the study

Design outcomes

Primary

Measure	Time frame
reduction in the EDSS functional system score	four months

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026